NGM Biopharmaceuticals, Inc. Common Stock
NGM
NGM was delisted on the 4th of April, 2024.
73 hedge funds and large institutions have $402M invested in NGM Biopharmaceuticals, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 24 increasing their positions, 17 reducing their positions, and 4 closing their positions.
350% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 4
41% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 17
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
24% more funds holding
Funds holding: 59 → 73 (+14)
4.72% more ownership
Funds ownership: 43.28% → 48% (+4.7%)
25% less capital invested
Capital invested by funds: $533M → $402M (-$131M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$17.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$16.3M |
| 3 |
PS
Peter Svennilson
|
+$14.7M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$3.73M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$2.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
-$1.76M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.3M |
| 3 |
BlackRock
New York
|
-$927K |
| 4 |
Morgan Stanley
New York
|
-$700K |
| 5 |
Goldman Sachs
New York
|
-$685K |
NGM Hedge Fund Activity: Q1 2020 in Review
73 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q1 2020, worth a combined $402M — down 25% from $533M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new NGM positions and 4 closed out — a net gain of 14 holders — while 24 added to existing stakes and 17 trimmed.
The largest buyer was Aquilo Capital Management, opening a new position worth an estimated $17.1M. The largest seller was Nuveen, cutting an estimated $1.76M.
- 73 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q1 2020, up from 59 in Q4 2019.
- Funds reported $402M of NGM Biopharmaceuticals, Inc. Common Stock stock for Q1 2020, down 25% quarter-over-quarter.
- 18 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q1 2020 and 4 closed out, a net change of +14 holders.
- The largest NGM Biopharmaceuticals, Inc. Common Stock buyer in Q1 2020 was Aquilo Capital Management, an estimated $17.1M added.
- The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q1 2020 was Nuveen, an estimated $1.76M sold.
Based on aggregated 13F filings for Q1 2020.